Surmasis Pharmaceutical
- Company typePrivate
- Founded2013
- HeadquartersDes Moines, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Surmasis Pharmaceutical firmographics
Firmographics- Name
- Surmasis Pharmaceutical
- Website
- https://surmasis.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Surmasis Pharmaceutical industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Surmasis Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- Des Moines
- HQ country
- United States
- HQ region
- North America
Markets served
Surmasis Pharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D
Surmasis Pharmaceutical product offering
Product offeringCore offering
Surmasis Pharmaceutical is a contract-based pharmaceutical manufacturing company that produces drug products on behalf of other organizations. Headquartered in Des Moines, United States, the firm employs 251-500 staff and was founded in 2013 to serve manufacturing needs across the pharmaceutical sector.
Differentiator
Problem solved
Functional benefit
Companies that use Surmasis Pharmaceutical
Customer profileIdeal customer profiles1 record
Surmasis Pharmaceutical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Surmasis Pharmaceutical competitors and assessment
Company assessmentBroad incumbents
- Catalent: One of the largest global CDMOs across softgel, biologics, oral and specialty dose forms. Directly comparable as a contract pharmaceutical manufacturer serving branded and generic pharma sponsors across multiple dosage forms.
- Thermo Fisher Scientific (Patheon CDMO): Operates a global contract pharmaceutical manufacturing network under its Patheon brand. Comparable as a broad incumbent CDMO offering API, drug product, clinical and commercial supply to pharma and biotech customers.
- Lonza: Swiss-headquartered CDMO with large-scale small molecule, biologics and cell-and-gene therapy manufacturing. Comparable to Surmasis as a full-service contract pharmaceutical manufacturer serving global pharma sponsors.
Direct peers
- Cambrex: US-based mid-sized CDMO specializing in small molecule API and finished dosage form contract manufacturing. Highly comparable to Surmasis as a similarly scaled contract pharmaceutical manufacturer serving innovator and generic pharma customers.
- Piramal Pharma Solutions: Contract development and manufacturing arm of Piramal offering API, intermediates, and drug product services globally. Comparable to Surmasis as a contract pharmaceutical manufacturer targeting complex and specialty therapies.
- Siegfried Holding: Swiss CDMO focused on API and finished drug product contract manufacturing for branded and generic pharma. Comparable to Surmasis as a mid-sized contract pharmaceutical manufacturer with a similar service scope.
- Aenova: European-headquartered CDMO with solid dosage form and sterile manufacturing capabilities serving pharma and consumer health customers. Comparable to Surmasis as a mid-sized contract pharmaceutical manufacturer serving multiple dosage forms.
- Recipharm: European CDMO offering contract development and manufacturing services across multiple dosage forms. Comparable to Surmasis as a similarly scaled contract pharmaceutical manufacturer with multi-site operations.
Emerging players
- WuXi STA (WuXi AppTec): Asia-based CDMO offering API and drug product development and manufacturing services globally. Comparable to Surmasis as a contract pharmaceutical manufacturer, though larger and serving a more international customer base.
- BIOVECTRA: North American CDMO offering contract manufacturing and development services in small molecule API and biologics. Comparable to Surmasis as a mid-sized contract pharmaceutical manufacturer operating in a similar competitive tier.
Market position
Customer concentration
Surmasis Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Surmasis Pharmaceutical leadership team
Management profileNumber of profiles
Surmasis Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Surmasis Pharmaceutical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Surmasis Pharmaceutical
What does Surmasis Pharmaceutical do?
Surmasis Pharmaceutical is a contract-based pharmaceutical manufacturing company that produces drug products on behalf of other organizations. Headquartered in Des Moines, United States, the firm employs 251-500 staff and was founded in 2013 to serve manufacturing needs across the pharmaceutical sector.
When was Surmasis Pharmaceutical founded?
Surmasis Pharmaceutical was founded in 2013. It employs 251 to 500 people.
Where is Surmasis Pharmaceutical based?
Surmasis Pharmaceutical is headquartered in Des Moines, United States, in the North America region.
Who are Surmasis Pharmaceutical's main competitors?
Broad incumbents on record are Catalent, Thermo Fisher Scientific (Patheon CDMO) and Lonza. Direct peers are Cambrex, Piramal Pharma Solutions, Siegfried Holding, Aenova and Recipharm. Emerging players are WuXi STA (WuXi AppTec) and BIOVECTRA.
Does Surmasis Pharmaceutical have an API?
No public API is recorded for Surmasis Pharmaceutical.
What industry is Surmasis Pharmaceutical in?
Surmasis Pharmaceutical's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.